B-CELL MALIGNANCY
Clinical trials for B-CELL MALIGNANCY explained in plain language.
Never miss a new study
Get alerted when new B-CELL MALIGNANCY trials appear
Sign up with your email to follow new studies for B-CELL MALIGNANCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for tough blood cancers
Disease control Recruiting nowThis study tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas. Participants must have tried at least two prior treatments without success or had side effects. The main goals ar…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1 • Sponsor: Carna Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
New drug targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new drug called BGB-16673 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The goal is to find the best dose and see if it is safe and shrinks tumors. About 146 Chinese adults will take part in this …
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
New Protein-Destroying drug shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New hope for hard-to-treat blood cancers: experimental combo therapy enters human trials
Disease control Recruiting nowThis study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The goal is to find safe doses …
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
CRISPR Gene-Editing takes on blood cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CTX112 for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor immune cells that can target and kill cancer cells. The trial…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 07, 2026 18:42 UTC